AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

IMMUTEP LTD

0.053

-0.003-5.36%

Volume:6.24M

Turnover:333.27K

Market Cap:78.11M

PE:-0.98

High:0.054

Open:0.054

Low:0.051

Close:0.056

52wk High:0.470

52wk Low:0.028

Shares:1.47B

Float Shares:1.23B

Volume Ratio:5.09

T/O Rate:0.51%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.054

EPS(LYR):-0.054

ROE:-77.31%

ROA:-42.45%

PB:1.27

PE(LYR):-0.98

Loading ...

Overview Company News Filings

Immutep reports positive interim Phase I data for autoimmune drug candidate IMP761 at EULAR 2026

Immutep - Efti + Soc Shows Median Overall Survival Improvement of 7.7 Months in Alc Responders

THOMSON REUTERS

Immutep - Announces Results From 5 Clinical Trials of Eftilagimod Alfa in Late-Stage Cancer

THOMSON REUTERS

Immutep Reports Survival Benefit Linked to Immune Response in Efti Clinical Trial Analysis

MT Newswires Live

Immutep says eftilagimod alfa plus standard care boosts overall survival in late-stage cancer study analysis

Immutep executives face securities class action after ADRs plunge 83% on trial collapse

Immutep Receives Nasdaq Notice of Bid Price Deficiency

THOMSON REUTERS

Immutep gets Nasdaq notice for breaching US$1 minimum bid price rule

BRIEF-Immutep Receives NASDAQ Notice Of Minimum Bid Price Non-Compliance

Immutep Ltd - Receives Nasdaq Notice of Minimum Bid Price Non-Compliance

THOMSON REUTERS

Immutep Ltd - Has 180 Days Until October 26, 2026 to Regain Nasdaq Compliance

THOMSON REUTERS

Immutep Ltd - Remains Listed on ASX; Nasdaq Notice Does Not Affect ASX Trading

THOMSON REUTERS

Immutep Says Bank of New York Mellon Increases Stake

MT Newswires Live

Immutep says ASCO accepts poster on eftilagimod alfa in metastatic cancer patients

Immutep Says JPMorgan Chase Cut Stake; Shares Down 9%

MT Newswires Live

ASX Runners of the Week: Bison, Genetic Signatures, Narryer & Immutep

The West Australian

Immutep files beneficial ownership Form 3 for director Elisabeth Amanda Boyce

BUZZ-Australia's Immutep extends gain on FDA orphan drug status for cancer drug

BRIEF-Immutep Ltd Says FDA Granted Orphan Drug Designation For Eftilagimod alfa In Soft Tissue Sarcoma

Immutep wins FDA orphan drug designation for eftilagimod alfa in soft tissue sarcoma

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/IMM.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IMM.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","market":"AU","secType":"STK","nameCN":"IMMUTEP LTD","latestPrice":0.053,"timestamp":1789345699649,"preClose":0.056,"halted":0,"volume":6244607,"delay":0,"changeRate":-0.05357142857142862,"nameEN":"IMMUTEP LTD","floatShares":1228247159,"shares":1473721306,"eps":-0.0539,"marketStatus":"Trading","change":-0.003,"latestTime":"09-14 10:28:48 AEST","open":0.054,"high":0.054,"low":0.051,"amount":333273,"amplitude":0.053571,"askPrice":0.053,"askSize":536444,"bidPrice":0.052,"bidSize":544736,"shortable":3,"etf":0,"ttmEps":-0.0539,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789365600000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.056,"openAndCloseTimeList":[[1789344000000,1789365600000]],"volumeRatio":5.087701,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"IMM.AU","preClose":0.056,"auctionPrice":0.054,"auctionVolume":1829507,"auctionTime":1789343947258,"referenceTime":1789122603091,"auction":1,"marketStatus":"盘前竞价","timestamp":1789343947258}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","floatShares":1228247159,"roa":"-42.45%","roe":"-77.31%","lyrEps":-0.0539,"volumeRatio":5.087701,"shares":1473721306,"dividePrice":0,"high":0.054,"amplitude":0.053571,"preClose":0.056,"low":0.051,"week52Low":0.028,"pbRate":"1.27","psRate":"3.92","week52High":0.47,"institutionHeld":0,"latestPrice":0.053,"committee":0.007669,"eps":-0.0539,"divideRate":0,"volume":6244607,"delay":0,"ttmEps":-0.0539,"open":0.054,"prevYearClose":0.415,"prevWeekClose":0.056,"prevMonthClose":0.048,"prevQuarterClose":0.053,"fiveDayClose":0.046,"twentyDayClose":0.052,"sixtyDayClose":0.052,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMM.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-06-05","symbol":"IMM.AU","defaultRemindTime":1717545600000,"type":"split","dateTimestamp":1717509600000,"forFactor":948148,"toFactor":1000000,"ratio":0.9481480000000001}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMM.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMM.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2640737180","title":"Immutep reports positive interim Phase I data for autoimmune drug candidate IMP761 at EULAR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640737180","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640737180?lang=en_us&edition=fundamental","pubTime":"2026-06-04 08:11","pubTimestamp":1780531906,"startTime":"0","endTime":"0","summary":"Immutep flagged positive interim Phase I data for autoimmune candidate IMP761, with results set for presentation at EULAR 2026 on June 4.The first-in-human trial in healthy volunteers met its primary goal, showing favorable safety and tolerability.Early readouts showed pharmacodynamic activity consistent with immunosuppressive effects versus placebo, supporting further development in autoimmune disease.The pharmacokinetic profile supports dosing about once every four weeks, shaping the program’s Phase II planning.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on June 04, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL3NVp6T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638698766","title":"Immutep - Efti + Soc Shows Median Overall Survival Improvement of 7.7 Months in Alc Responders","url":"https://stock-news.laohu8.com/highlight/detail?id=2638698766","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638698766?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:10","pubTimestamp":1779970241,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nFWN4250NC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638698713","title":"Immutep - Announces Results From 5 Clinical Trials of Eftilagimod Alfa in Late-Stage Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2638698713","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638698713?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:10","pubTimestamp":1779970241,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nFWN4250NC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638365224","title":"Immutep Reports Survival Benefit Linked to Immune Response in Efti Clinical Trial Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2638365224","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638365224?lang=en_us&edition=fundamental","pubTime":"2026-05-28 13:56","pubTimestamp":1779947778,"startTime":"0","endTime":"0","summary":"Immutep  said a systematic evaluation of five clinical trials of eftilagimod alfa , an antigen-presenting cell  activator, in combination with standard-of-care therapies in late-stage cancer patients showed a significant increase in circulating absolute lymphocyte count  compared to standard-of-care alone, according to a Thursday Australian bourse filing.The company said increased ALC was significantly associated with improved clinical outcomes, with ALC responders in the efti plus standard-of-care group showing a clinically meaningful median overall survival improvement of 7.7 months compared to ALC non-responders, with no corresponding association observed in the standard-of-care alone group.\"The findings link the immune-activating effect of efti measured in patients' blood with meaningful and significant survival improvements observed in previous clinical trials,\" said Immutep's Chief Scientific Officer, Frederic Triebel, adding that the studies highlighted a key connection with eft","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4534","BK7094","BK7095","LU0157215616.USD","LU0149725797.USD","LU2083900584.USD","LU1066051498.USD","LU1778281490.HKD","ALC.AU","LU2265009873.SGD","LU0314104364.USD","LU0882574139.USD","LU1066051811.HKD","LU2417539215.USD","LU1804176565.USD","APC","LU2237443549.SGD","LU2237443622.USD","LU1674673428.USD","LU1066051225.USD","LU2456880835.USD","APC.AU","LU0077335932.USD","LU1935042991.SGD","BK4198","LU0786609619.USD","LU2420271590.USD","BK7508","LU2236285917.USD","LU1066053197.SGD","LU1366192091.USD","LU1674673691.USD","LU1935042215.USD","LU0053666078.USD","IMM.AU","ALC","LU2237443978.SGD","LU0170899867.USD","BK4214","BK7067","LU1935043023.USD","LU1366333091.USD","LU1496350171.SGD","LU1935042488.USD","LU1718418525.SGD","LU2237443382.USD","LU1935043536.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638658881","title":"Immutep says eftilagimod alfa plus standard care boosts overall survival in late-stage cancer study analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2638658881","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638658881?lang=en_us&edition=fundamental","pubTime":"2026-05-28 09:04","pubTimestamp":1779930262,"startTime":"0","endTime":"0","summary":"Immutep disclosed a pooled evaluation of five eftilagimod alfa combination trials in late-stage cancers, linking immune activation to better survival outcomes.Patients showing a treatment-related immune response tended to live longer than non-responders, a pattern not seen with standard therapy alone.Findings were consistent across multiple tumor types and across combinations with chemotherapy or PD-1-based immunotherapy.The analysis excluded the discontinued TACTI-004 Phase III lung cancer trial, limiting read-through to earlier-stage studies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on May 28, 2026, and is solely responsible for the information contain","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL9l2P64:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637333915","title":"Immutep executives face securities class action after ADRs plunge 83% on trial collapse","url":"https://stock-news.laohu8.com/highlight/detail?id=2637333915","media":"Reuters","labels":["executive","policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637333915?lang=en_us&edition=fundamental","pubTime":"2026-05-21 21:08","pubTimestamp":1779368914,"startTime":"0","endTime":"0","summary":"Immutep faces a securities class action tied to investor purchases from March 24, 2025 to March 12, 2026, centered on the collapse of the TACTI-004 trial.ADRs fell to $0.48 from $2.76 on March 13, 2026, a one-day drop of 83% that erased $2.28 per share.The suit names CEO Marc Voigt, Chief Scientific Officer Frédéric Triebel, and Chief Medical Officer Stephan Winckels as individual defendants under Section 20 control-person claims.Plaintiffs allege the executives misled investors about trial progress while holding adverse non-public interim data, including through Sarbanes-Oxley certifications tied to SEC filings.A court deadline of July 6, 2026 has been set for investors seeking appointment as lead plaintiff.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL3s7WXt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Immutep executives face securities class action after ADRs plunge 83% on trial collapse","news_tag":"executive,policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631090631","title":"Immutep Receives Nasdaq Notice of Bid Price Deficiency","url":"https://stock-news.laohu8.com/highlight/detail?id=2631090631","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631090631?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:00","pubTimestamp":1777550406,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nTUA5TB9FC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","IMM.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631743315","title":"Immutep gets Nasdaq notice for breaching US$1 minimum bid price rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2631743315","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631743315?lang=en_us&edition=fundamental","pubTime":"2026-04-30 09:39","pubTimestamp":1777513157,"startTime":"0","endTime":"0","summary":"Immutep received a Nasdaq notice of non-compliance with minimum bid price rule requiring at least US$ 1 per share.Nasdaq granted a 180-day compliance window expiring Oct. 26, 2026 to regain compliance.Compliance can be restored if ADS closing bid price reaches at least US$ 1 for 10 consecutive business days.Notice has no immediate impact on Nasdaq listing or trading of Immutep ADS.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on April 30, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDLjS1mR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631015571","title":"BRIEF-Immutep Receives NASDAQ Notice Of Minimum Bid Price Non-Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2631015571","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631015571?lang=en_us&edition=fundamental","pubTime":"2026-04-30 09:33","pubTimestamp":1777512781,"startTime":"0","endTime":"0","summary":"BRIEF-Immutep Receives NASDAQ Notice Of Minimum Bid Price Non-ComplianceApril 30  - Immutep Ltd IMM.AX:RECEIVES NASDAQ NOTICE OF MINIMUM BID PRICE NON-COMPLIANCEREMAINS LISTED ON ASX; NASDAQ NOTICE DOES NOT AFFECT ASX TRADINGHAS 180 DAYS UNTIL OCTOBER 26, 2026 TO REGAIN NASDAQ COMPLIANCEFurther company coverage: IMM.AX ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nFWN41C1U5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631857337","title":"Immutep Ltd - Receives Nasdaq Notice of Minimum Bid Price Non-Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2631857337","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631857337?lang=en_us&edition=fundamental","pubTime":"2026-04-30 07:22","pubTimestamp":1777504933,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nFWN41C1U5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631531573","title":"Immutep Ltd - Has 180 Days Until October 26, 2026 to Regain Nasdaq Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2631531573","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631531573?lang=en_us&edition=fundamental","pubTime":"2026-04-30 07:22","pubTimestamp":1777504933,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nFWN41C1U5:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMM.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631457353","title":"Immutep Ltd - Remains Listed on ASX; Nasdaq Notice Does Not Affect ASX Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2631457353","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631457353?lang=en_us&edition=fundamental","pubTime":"2026-04-30 07:22","pubTimestamp":1777504933,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nFWN41C1U5:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMM.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630337859","title":"Immutep Says Bank of New York Mellon Increases Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2630337859","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630337859?lang=en_us&edition=fundamental","pubTime":"2026-04-27 08:21","pubTimestamp":1777249274,"startTime":"0","endTime":"0","summary":"Immutep  received notice that Bank of New York Mellon and its affiliated entities increased their holdings in the company to 21.11% from 20.08%, according to a Monday filing with the Australian bourse.Bank of New York Mellon and its affiliates now owns over 311 million shares in the company, the filing said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1571399168.USD","LU0980610538.SGD","BK4585","LU0130517989.USD","IMM.AU","LU0477156953.USD","LU0130102774.USD","BK4588","BK4559","LU1201861249.SGD","BK7067","LU1699723380.USD","BK4135","LU0648001328.SGD","BK7508","BK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629985870","title":"Immutep says ASCO accepts poster on eftilagimod alfa in metastatic cancer patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2629985870","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629985870?lang=en_us&edition=fundamental","pubTime":"2026-04-22 10:20","pubTimestamp":1776824450,"startTime":"0","endTime":"0","summary":"Immutep flagged an abstract on its cancer immunotherapy candidate eftilagimod alfa for poster presentation at ASCO 2026, with results scheduled for May 30.Poster data are set to show cumulative clinical and translational findings that the drug drives rapid, sustained immune-cell activation in metastatic cancer patients.Immutep expects the analysis to link immune activation signals with better overall survival outcomes across multiple late-stage cancer studies, supporting the program’s clinical rationale.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on April 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDLb644WR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628205632","title":"Immutep Says JPMorgan Chase Cut Stake; Shares Down 9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628205632","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628205632?lang=en_us&edition=fundamental","pubTime":"2026-04-17 14:04","pubTimestamp":1776405844,"startTime":"0","endTime":"0","summary":"Immutep (ASX:IMM) said JPMorgan Chase and its affiliates cut their stake in the company on Tuesday to 5.43% or about 80.1 million shares from 6.94% or roughly 102.3 million shares, according to a Friday filing with the Australian bourse.Shares of Immutep were down 9% in recent Friday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2236285917.USD","LU2106854487.HKD","LU2430703251.USD","BK4504","LU1267930490.SGD","LU2417539215.USD","LU1974910355.USD","LU2211815571.USD","LU1551013425.SGD","LU0265550359.USD","JPMO","LU2237443978.SGD","JPM","LU0251132253.USD","LU0859254822.USD","LU0882574139.USD","LU0971096721.USD","LU0267386448.USD","IE00BLSP4452.SGD","IE00B1BXHZ80.USD","LU0345770308.USD","LU2023250843.SGD","IE00B1XK9C88.USD","IMM.AU","LU0211327993.USD","BK7067","LU0820562030.AUD","JPO","LU1261432733.SGD","BK4588","LU2430703178.SGD","LU0211331839.USD","SG9999002232.USD","LU1548497426.USD","LU0203347892.USD","LU2462157665.USD","LU0820561818.USD","LU2264538146.SGD","IE00BZ1G4Q59.USD","LU2746668974.SGD","LU1145028129.USD","BK4581","LU0048584097.USD","LU1366192091.USD","BK4516","IE00BYXW3230.USD","SG9999002224.SGD","LU0787776722.HKD","LU0868494617.USD","LU2242649171.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628278514","title":"ASX Runners of the Week: Bison, Genetic Signatures, Narryer & Immutep","url":"https://stock-news.laohu8.com/highlight/detail?id=2628278514","media":"The West Australian","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628278514?lang=en_us&edition=fundamental","pubTime":"2026-04-17 06:27","pubTimestamp":1776378463,"startTime":"0","endTime":"0","summary":"The Bulls N’ Bears ASX Runner of the Week is… Bison Resources, which exploded on debut, as punters piled into its prime Nevada gold-silver projects amid ongoing fuel security chaos.","market":"us","thumbnail":"https://images.thewest.com.au/publication/C-22156398/f3ba145e5bde0aa97d4b38a2ae55d7e52f82c4d9.jpg","type":0,"news_type":0,"thumbnails":["https://images.thewest.com.au/publication/C-22156398/f3ba145e5bde0aa97d4b38a2ae55d7e52f82c4d9.jpg"],"rights":{"source":"thewest_stock","url":"https://thewest.com.au/business/bulls-n-bears/asx-runners-of-the-week-bison-genetic-signatures-narryer-immutep-c-22156398","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thewest.com.au/business/bulls-n-bears/asx-runners-of-the-week-bison-genetic-signatures-narryer-immutep-c-22156398","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thewest_stock","symbols":["DZZ","GSS.AU","BK4183","FGDL","JNUG","OUNZ","BEGS","SGOL","CEF","IAUI","IAUM","AAAU","BK7104","XME","BK4588","JDST","GOLY","PICK","BK7067","BK7095","BK7508","IAU","IE0009354923.USD","BK7501","BAR","GDXU","ODD","UGL","BSR.AU","GBUG","GLL","GLDM","DBC","DUST","GDXJ","NYM.AU","PHYS","DGP","RING","GDXD","BTGD","BK4535","BK4585","USG","GLTR","GDX","IMM.AU","DULL","GDXY","BK7048"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627299905","title":"Immutep files beneficial ownership Form 3 for director Elisabeth Amanda Boyce","url":"https://stock-news.laohu8.com/highlight/detail?id=2627299905","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627299905?lang=en_us&edition=fundamental","pubTime":"2026-04-16 18:06","pubTimestamp":1776334014,"startTime":"0","endTime":"0","summary":"Immutep director Elisabeth Amanda Boyce filed an initial U.S. SEC Form 3 reporting 423,288 ordinary shares held directly as of March 18, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 16, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL5J4M9T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627257758","title":"BUZZ-Australia's Immutep extends gain on FDA orphan drug status for cancer drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2627257758","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627257758?lang=en_us&edition=fundamental","pubTime":"2026-04-16 10:24","pubTimestamp":1776306262,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Immutep extends gain on FDA orphan drug status for cancer drug** Shares of Australian biotechnology firm Immutep IMM.AX rise as much as 22.2% to A$0.075, their highest since March 6**","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nL4N40Z06C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627476113","title":"BRIEF-Immutep Ltd Says FDA Granted Orphan Drug Designation For Eftilagimod alfa In Soft Tissue Sarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2627476113","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627476113?lang=en_us&edition=fundamental","pubTime":"2026-04-15 09:21","pubTimestamp":1776216119,"startTime":"0","endTime":"0","summary":"BRIEF-Immutep Ltd Says FDA Granted Orphan Drug Designation For Eftilagimod alfa In Soft Tissue SarcomaApril 15 (Reuters) - Immutep Ltd IMM.AX:IMMUTEP LTD - FDA GRANTS ORPHAN DRUG DESIGNATION FOR EFTILAGIMOD ALFA IN SOFT TISSUE SARCOMASource text: ID:nASX4fL5nrFurther company coverage: IMM.AX","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nFWN40X171:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627753974","title":"Immutep wins FDA orphan drug designation for eftilagimod alfa in soft tissue sarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2627753974","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627753974?lang=en_us&edition=fundamental","pubTime":"2026-04-15 08:41","pubTimestamp":1776213697,"startTime":"0","endTime":"0","summary":"Designation supports potential late-stage development in resectable disease following Phase II EFTISARC-NEO results.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on April 15, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL9NDDby:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":60,"code":"91000000","status":"200"}]}}